BELLINI: a renaissance for an era of precision therapy in multiple myeloma Comment

被引：5
|
作者：
Ghobrial, Irene [1 ]
机构：
[1] Harvard Univ, Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
LANCET ONCOLOGY | 2020年 / 21卷 / 12期
关键词：
SENSITIVITY;
D O I：
10.1016/S1470-2045(20)30587-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1547 / 1549
页数：4
相关论文
共 50 条
  • [21] Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma
    Short, K. Detweiler
    Rajkumar, S. V.
    Larson, D.
    Buadi, F.
    Hayman, S.
    Dispenzieri, A.
    Gertz, M.
    Kumar, S.
    Mikhael, J.
    Roy, V.
    Kyle, R. A.
    Lacy, M. Q.
    LEUKEMIA, 2011, 25 (06) : 906 - 908
  • [22] Targets Selection for Precision Therapy of Relapsed/Refractory Multiple Myeloma: the Latest Advancements
    Wang, Zhen
    Song, Yanqi
    Guo, Honglei
    Yan, Yuting
    Ma, Lin
    Liu, Baoshan
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2025, 26 (02) : 128 - 141
  • [23] Outcomes of Vdpace for Relapsed/Refractory Multiple Myeloma in the Era of Daratumumab Based Therapy
    Venkatesh, Priyanka
    Khasawneh, Ghena
    Hashmi, Hamza
    Alkharabsheh, Omar
    Paul, Barry
    Skikne, Barry S.
    Mahmoudjafari, Zahra
    Ahmed, Nausheen
    Abdallah, Al-Ola
    Atrash, Shebli
    BLOOD, 2023, 142
  • [24] Therapy Related MDS/AML In Multiple Myeloma Patients In The Era Of Novel Agents
    Gertz, Morie A.
    Hayman, Suzanne R.
    Dingli, David
    Dispenzieri, Angela
    Kapoor, Prashant
    Kumar, Shaji K.
    Lacy, Martha Q.
    Leung, Nelson
    Lin, Yi
    Lust, John A.
    Mikhael, Joseph R.
    Rajkumar, S. Vincent
    Russell, Stephen J.
    Zeldenrust, Steven R.
    Kyle, Robert
    Buadi, Francis K.
    BLOOD, 2013, 122 (21)
  • [25] BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma
    Cho, Shih-Feng
    Lin, Liang
    Xing, Lijie
    Li, Yuyin
    Yu, Tengteng
    Anderson, Kenneth C.
    Tai, Yu-Tzu
    CANCERS, 2020, 12 (06) : 1 - 29
  • [26] Infection Risk in Patients with Multiple Myeloma during the Era of Monoclonal Antibody Therapy
    Hoffman, Stephanie
    Kandarpa, Malathi
    Ye, Jing Christine
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S256 - S257
  • [27] IgM Multiple Myeloma in the Era of Novel Therapy: Clinicopathologic Study of 14 Cases
    Angelova, Evgeniya A.
    Lu, Xinyan
    Li, Shaoying
    Medeiros, L. Jeffrey
    Lin, Pei
    MODERN PATHOLOGY, 2017, 30 : 337A - 337A
  • [28] IgM Multiple Myeloma in the Era of Novel Therapy: Clinicopathologic Study of 14 Cases
    Angelova, Evgeniya A.
    Lu, Xinyan
    Li, Shaoying
    Medeiros, L. Jeffrey
    Lin, Pei
    LABORATORY INVESTIGATION, 2017, 97 : 337A - 337A
  • [29] The era of lenalidomide maintenance therapy in multiple myeloma: settings for achieving best outcomes
    Kesireddy, Meghana
    Holstein, Sarah A.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2022, 15 (01) : 19 - 31
  • [30] Thrombosis in the modern era of multiple myeloma
    Rubinstein, Samuel M.
    Tuchman, Sascha A.
    BLOOD, 2020, 136 (09) : 1019 - 1021
12345